It has been found that BAK can increase serum ALT, TBIL, and TBA and reduce CYP7a1, HMG-CoA, PPARα, and SREBP-2 mRNA expression, resulting in cholestasis hepatotoxicity. The gene discussed is SREBF2; the disease is cholestasis.